The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review-Reference-Cited by-同舟云学术

The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review

Published:2022-07 Issue:7 Volume:25 Page:1235-1252
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Saunders Hailey,Pham Ba’,Loong Desmond,Mishra Sujata,Ashoor Huda M.,Antony Jesmin,Darvesh Nazia,Bains Silkan K.,Jamieson Margaret,Plett Donna,Trivedi Srushhti,Yu Catherine H.,Straus Sharon E.,Tricco Andrea C.,Isaranuwatchai Wanrudee

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference74 articles.

1. Insulin analogues in type 1 diabetes mellitus: getting better all the time;Mathieu;Nat Rev Endocrinol,2017

2. Improving the treatment of patients with diabetes using insulin analogues: current findings and future directions;Lefever;Expert Opin Drug Saf,2021

3. Insulin - pharmacology, therapeutic regimens, and principles of intensive insulin therapy;Donner,2019

4. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040;Ogurtsova;Diabetes Res Clin Pract,2017

5. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview;Nathan;Diabetes Care,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association;Diabetes & Metabolism Journal;2024-07-31

2. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study;Diabetes, Obesity and Metabolism;2024-04

3. A Systematic Review of Economic Evaluations of Insulin for the Management of Type 2 Diabetes;Diabetology;2023-10-13

4. New Insulins, Biosimilars, and Insulin Therapy;Diabetes Technology & Therapeutics;2023-02-01